Our COVID-19 solutions key facts

We are working with scientific partners to develop a broad portfolio of potential COVID-19 solutions

Our science and technology

We are using our adjuvant technology to investigate several adjuvanted COVID-19 vaccines, partnering with Sanofi, Medicago of Canada and SK Bioscience of South Korea. Our collaborations with Sanofi and Medicago are now in late-stage trials.

We are also investigating next generation COVID-19 vaccines, expanding our work with mRNA technology specialist CureVac of Germany, to jointly develop next-generation mRNA COVID-19 vaccines which could address multiple variants in a single vaccine.

In addition to vaccines, we are investigating several potential treatments for COVID-19 patients.

Our collaboration with Vir Biotechnology includes development of two new monoclonal antibodies which could be used as therapeutic or preventative options to fight this and future outbreaks.

One of these monoclonal antibodies, has been authorised for emergency use in the US and has been granted a marketing authorisation in the EU, conditional marketing authorisation in Great Britain, provisional marketing authorisation in Australia, and conditional marketing authorisation in Saudi Arabia. It has also been approved via Japan’s Special Approval for Emergency Pathway. Temporary authorisations have also been granted in 12 other countries.

We have also received binding agreements for the sale of more than 1.7m doses of this antibody.

In addition, the companies are investigating an intramuscular (IM) administration which could potentially improve access to the antibody in some parts of the world.

A second antibody from our collaboration with Vir Biotechnology is also being investigated as a potential COVID-19 treatment.

Across all of our COVID-19 solutions, we are committed to: working in partnership; taking a global approach; ensuring a commitment to access; and supporting future pandemic preparedness.

Our existing products

We are ensuring continuous supply of our medicines, vaccines and consumer healthcare products with 20,000 employees working in our R&D and manufacturing sites around the world.

We have also donated over 1.4 million products across 27 countries.

Our capabilities and expert facilities

In addition to our own COVID-19 vaccine development work, we have made our world leading manufacturing facilities available to other companies to support the global vaccine production effort.

We have set up specialised laboratory space to help support national diagnostic testing in the UK and Belgium.

In addition, we are providing free curriculum STEM resources online in the UK and US, supporting teachers and students with in school and remote learning.

Supporting frontline health workers

We have made a $10 million donation to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to prevent, detect, and manage the pandemic in support of frontline health workers.

We have donated lab equipment, instruments, and scientific kits to support government testing and over 800,000 PPE units to protect frontline health workers in 34 countries.

What is an adjuvant?

An adjuvant can be added to a vaccine to boost the body’s immune response, which means less vaccine is needed for the same result. This is particularly important in a pandemic as more vaccine doses can be available to protect people around the world.